Milestone Pharmaceuticals Inc.

MIST Nasdaq SEC CIK 1408443
Follow Milestone Pharmaceuticals Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $963K
Net income −$25.8M −116.4% vs same quarter last year
EPS, diluted −$0.18 −50% vs same quarter last year
Operating cash flow −$25.2M −158.9% vs same quarter last year
Revenue by quarter
$0
$0
$0
$238K
$559K
$963K
Q1 25 Q2 25 Q3 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income9 fiscal years
−$60M−$40M−$20M$0FY17FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearNet income
FY25−$63.1K
FY24−$41.5K
FY23−$59.7K
FY22−$58.4M
FY21−$42.9M
FY20−$50M
FY19−$55.2M
FY18-
FY17-
Free cash flowOperating cash flow minus capital expenditure
−$60M−$40M−$20M$0FY17FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25−$49.3M
FY24−$28.9M
FY23−$46.5M
FY22−$52.7M
FY21-
FY20-
FY19−$51.6M
FY18−$21.1M
FY17-